Document is current
Any future updates will be listed below
-
Authors
Deiman, Frederik E. https://orcid.org/0000-0001-9793-4683
Bömer, Nils https://orcid.org/0000-0001-5926-6960
Davidsson, Pia
Später, Daniela
Linders, Annet N.
Dias, Itamar B.
Arevalo Gomez, Karla F.
Esquivel Gaytan, Antonio
Zhu, Jumo
Walentinsson, Anna
Engberg, Susanna
Hattersley, Neil
Etal, Damla
Ahlstrom, Christine
Mullick, Adam E. https://orcid.org/0000-0003-4600-961X
Hansson, Kenny M.
Silljé, Herman H. W.
Grote Beverborg, Niels
van der Meer, Peter
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 15 December 2025
Revised: 14 April 2026
Accepted: 7 May 2026
First Online: 28 May 2026
Competing interests
: This study was supported by a research grant from AstraZeneca. Frederik Deiman, Annet Linders, Itamar Dias, Karla Arevalo Gomez, Antonio Esquivel Gaytan, Jumo Zhu, Nils Bömer, and Niels Grote Beverborg declare no conflict of interest. Herman Silljé reports grants from AstraZeneca, Novo Nordisk and Pfizer outside the submitted work. Peter van der Meer reports grants from AstraZeneca, Ionis Pharmaceuticals, Novo Nordisk, Novartis, Pharmacosmos, Vifor Pharma, Pfizer, Pharma Nord, and BridgeBio outside the submitted work. Pia Davidsson, Daniela Später, Anna Walentinsson, Susanna Engberg, Neil Hattersley, Damla Etal, Christine Ahlstrom and Kenny Hansson are employed by AstraZeneca. Adam Mullick is employed by Ionis Pharmaceuticals.
